Data-Driven Health Innovation and Privacy Regulation-Reference-Cited by-同舟云学术

Data-Driven Health Innovation and Privacy Regulation

Published:2023-11-01 Issue:1 Volume:24 Page:329-338
ISSN:1935-1682
Container-title:The B.E. Journal of Economic Analysis & Policy
language:en
Short-container-title:

Author:

Conti Chiara¹,D’Annunzio Anna²,Reverberi Pierfrancesco¹

Affiliation:

1. Department of Computer, Control, and Management Engineering , Sapienza University of Rome , Roma , Italy

2. TBS Business School , Toulouse , France

Abstract

Abstract Data-driven health innovation may lead to develop targeted treatments using health data. We consider privacy-sensitive patients who may decide to share personal health data if compensated. Each patient does not internalize the impact of sharing data on drug innovation. We show that investment incentives in targeted treatments are too weak as long as such innovation has a public good nature so that patients can free ride on sharing health data. Then, privacy protection measures reducing data sharing risks can promote pharmaceutical R&D and social welfare.

Funder

Agence Nationale de la Recherche

Sapienza University of Rome

Publisher

Walter de Gruyter GmbH

Subject

Economics, Econometrics and Finance (miscellaneous),Economics and Econometrics

Link

https://www.degruyter.com/document/doi/10.1515/bejeap-2023-0020/pdf

Reference14 articles.

1. Antoñanzas, F., C. A. Juárez-Castelló, and R. Rodríguez-Ibeas. 2015. “Some Economics on Personalized and Predictive Medicine.” The European Journal of Health Economics 16: 985–94. https://doi.org/10.1007/s10198-014-0647-8.

2. Bardey, D., A. Bommier, and B. Jullien. 2010. “Retail Price Regulation and Innovation: Reference Pricing in the Pharmaceuticals Industry.” Journal of Health Economics 29: 303–16. https://doi.org/10.1016/j.jhealeco.2009.11.015.

3. Barigozzi, F., and I. Jelovac. 2020. “Research Funding and Price Negotiation for New Drugs.” Health Economics 29: 83–96. https://doi.org/10.1002/hec.4113.

4. Brekke, K. R., D. M. Dalen, and O. R. Straume. 2022. “Competing with Precision: Incentives for Developing Predictive Biomarker Tests.” NHH Discussion Paper, 06/22.

5. Conti, C., and P. Reverberi. 2021. “Price Discrimination and Product Quality under Opt-In Privacy Regulation.” Information Economics and Policy 55: 100912. https://doi.org/10.1016/j.infoecopol.2020.100912.